
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated strong revenue growth in key segments, with TAVR revenue increasing by 10.6% year-over-year, comfortably exceeding consensus estimates, and TMTT sales surging by 48.3% year-over-year, reflecting robust market demand and product adoption. The company anticipates continued growth in TAVR and TMTT, projecting TAVR growth of 6-8% year-over-year and TMTT revenue between $740 million to $780 million, indicating potential for substantial market capture and expansion. Furthermore, management expresses heightened confidence in achieving its 2026 sales guidance of 8-10% year-over-year growth, reinforcing the outlook for sustained revenue momentum through 2025 and beyond.
Bears say
Edwards Lifesciences experienced a significant operational margin miss, primarily due to elevated selling, general, and administrative expenses that totaled $603 million, surpassing initial consensus expectations. Additionally, while transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid technologies (TMTT) sales exceeded consensus estimates, the overall performance was dragged down by underwhelming surgical structural heart sales, which fell short by approximately $4.5 million. The company faces multiple risks that threaten its growth trajectory, including potential delays in market growth re-acceleration, increasing competition, and challenges in gaining market share for its TMTT products, all of which contribute to a cautious outlook for the stock.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares